SINO BIOPHARM (01177) News

Sino Biopharm: TQB3454, an IDH1 inhibitor, achieves positive results in Phase III clinical trial for biliary tract cancer.

Gelonghui, March 12th丨Sino Biopharm (01177.HK) announced that the Phase III clinical study of TQB3454, a Class 1 innovative drug independently developed by its subsidiary Zhengdatianqing for treating advanced biliary tract cancer with IDH1 mutation as an "IDH1 inhibitor," has completed the interim analysis predefined in the protocol. The Independent Data Monitoring Committee (IDMC) determined that both primary endpoints, progression-free survival (PFS) and overall survival (OS), reached the predefined thresholds for superiority. The group has communicated with the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration regarding the marketing application for this indication and received...

Gelonghui FinanceMar 12 17:04

HKEX Announcements Highlights | Swire Reports Net Profit of Approximately HKD 11.4 Billion in 2025, while Qz Group's Annual Revenue Increases by Over 20% Year-on-Year

①Swire Group achieved a net profit of approximately HKD 11.4 billion in 2025. How high was the growth rate? ②Quzhi Group's annual revenue increased by more than 20% year-on-year. What was its profitability performance like?

cls.cnMar 12 20:41

Hong Kong Stock Announcements | Laopu Gold issues a profit alert, expecting a net profit of approximately RMB 4.8 to 4.9 billion for the fiscal year 2025, representing a year-on-year increase of about 226% to 233%.

Cathay Pacific released its 2025 annual performance, with a profit attributable to shareholders of HKD 10.828 billion, representing a year-on-year increase of 9.51%; China Metallurgical Group's new contract value for the first two months reached RMB 132.44 billion, reflecting a year-on-year decrease of 6.49%.

Zhitong FinanceMar 12 09:05

Two Sessions Set New Course! Analysts Favor These Sectors as Fund Managers Map Out '2026 Investment Blueprint'

During the Two Sessions in 2026, the draft outline of the '15th Five-Year Plan' and the government work report not only provided a clear blueprint for economic development and policy direction but also signaled numerous investment opportunities.

Securities Times ChinaMar 9 08:54

Surging BD transactions and policy catalysts! The Hang Seng Medicine ETF (159892) surged by 3.67%, while the HK Connect Healthcare ETF (520510) rose by 2.89%, with its real-time turnover rate ranking first among similar products.

Gelonghui, March 6th | Today, the innovative drug sector rebounded strongly. The constituent stock 3SBio Inc. surged by 10%, driving the Hang Seng Medicine ETF (159892) to rise by 3.67%. The Stock Connect Healthcare ETF (520510) increased by 2.89%, with a turnover rate of 54.58%, ranking first among similar products. In terms of news: ① The 2026 Government Work Report identifies new quality productive forces as a core focus, listing biomedicine alongside integrated circuits, aerospace, and low-altitude economy for the first time, clearly defining it as a national 'emerging pillar industry.' It is expected that innovative drugs will receive more concentrated policy support, funding, and resource allocation. ② Business development (BD) transactions continue.

Gelonghui FinanceMar 6 13:01

The concept of innovative pharmaceuticals in Hong Kong stocks has gained momentum, with biomedicine emerging as a 'new pillar industry' for the first time. Both business development (BD) and financial performance are expected to serve as dual drivers.

The innovative drug sector strengthened during early trading. As of press time, 3SBio Inc. surged nearly 9%, Hutchison China MediTech rose over 8%, Innovent Bio climbed nearly 6%, Hengrui Pharma increased more than 5%, and Connaught Medical-B gained 5%.

Zhitong FinanceMar 6 10:22

Bank of America Securities has raised its target price for China Biologic Products (01177.HK) to HKD 8.9 and reiterated its "Buy" rating.

BofA Securities issued a research report stating that Sino Biopharm (01177.HK) has announced an exclusive licensing agreement with Sanofi for the global (including China) development, manufacturing, and commercialization of Sino Biopharm's JAK/ROCK inhibitor, Rovatirelin. Sino Biopharm is entitled to an upfront payment of $135 million, along with potential developmental, regulatory, and sales milestone payments of up to $1.395 billion, as well as tiered royalties based on the annual net sales of Rovatirelin. The report noted that reaching a licensing deal with multinational pharmaceutical company Sanofi reflects Sino Biopharm’s internal R&D capabilities.

AASTOCKSMar 5 10:45

HK Stocks Movement | Sino Biopharm (01177) Surges Over 5% as Rofacitinib License Granted to Sanofi, Potential Receipts Exceeding $1.5 Billion

Sino Biopharm (01177) surged over 5%. As of the time of writing, it was up 5.25%, trading at HKD 6.01, with a turnover of HKD 146 million.

Zhitong FinanceMar 5 10:06

Sanofi Bets up to $1.53B to License Blood Cancer Drug From Sino Biopharma Unit

Seeking AlphaMar 4 19:57

Middle East Conflict Impacts Financial Markets as Thai Stocks Plunge 8%, Triggering Circuit Breaker

Amid escalating tensions in the Middle East dampening market sentiment, Thailand's benchmark SET 50 index plummeted 8% today (April 4), triggering a market circuit breaker. The Stock Exchange of Thailand (SET) Index fell sharply by 8% at 12:18 PM local time today (April 4), immediately halting trading for 30 minutes. According to regulations, if the decline widens further to 15%, it will trigger another round of trading suspension. This downturn was mainly driven by heavyweights, including Delta Electronics' Thai subsidiary Teda Electronics and Gulf Development Pcl, which recorded significant losses. Sinopharm Group (0117

AASTOCKSMar 4 15:06

Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals

WSJMar 4 12:33

HKG Announcements | Techtronic Industries reports a 6.8% year-on-year increase in net profit to USD 1.2 billion for 2025, with a final dividend of HKD 1.32 per share.

Minmetals Resources (01208) released its annual performance report, showing a pre-tax profit of US$1.727 billion for the year, representing a year-on-year increase of 178%.

Zhitong FinanceMar 4 09:15

Sino Biopharm (01177) has entered into an exclusive licensing agreement with Sanofi for Rofacitinib.

Sino Biopharm (01177) announced that its subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), has entered into an exclusive licensing agreement with a wholly-owned subsidiary of Sanofi S.A. (Sanofi) for the global development, production, and commercialization of the group's JAK/ROCK inhibitor, Rovatitinib.

Zhitong FinanceMar 4 06:19

Hong Kong Stocks End Lower as Middle East Conflict Intensifies

MT NewswiresMar 2 16:51

Sino Biopharmaceutical Stock Slips 2.8% in Hong Kong

Dow JonesMar 2 16:33

CSC Financial: Chinese pharmaceutical companies possess engineering advantages; it is recommended to focus on leading innovators in asthma and COPD treatments.

The leading and in-depth deployment by Chinese pharmaceutical companies in targets such as IL-4Rα, TSLP, PDE3/4, and IL5, as well as their engineering advantages in long-acting technology, are expected to enable a leap from followers to leaders.

Zhitong FinanceMar 2 13:45

Hong Kong Stock Announcements | Yum China's total revenue for 2025 increased by 4% year-over-year to USD 11.8 billion.

CRRC Signal's attributable net profit for 2025 is RMB 3.661 billion, representing a year-on-year increase of 4.76%.

Zhitong FinanceMar 2 09:15

Hong Kong Stock Market Close (02.27) | Hang Seng Index rose by 0.95%; pharmaceuticals and metals concepts performed strongly; Sun Hung Kai Properties (00016) surged 7% post-results announcement.

The three major indexes of the Hong Kong stock market rebounded today, with both the Hang Seng Index and the Hang Seng Tech Index rising by more than 1% at one point. By the close of trading, the Hang Seng Index had increased by 0.95%, or 249.52 points, to reach 26,630.54 points.

Zhitong FinanceFeb 27 16:38

UBS Group forecasts that revenue in the healthcare and health sector will continue to grow by 10% this year, upgrading 3SBio Inc. (01530.HK) to its top pick.

UBS Group issued a research report stating that, based on the latest industry sales data and licensing transaction trends, it currently forecasts that the median revenue growth for its rated healthcare enterprises will be 16% in 2025 and 10% in 2026. The bank believes that the sales performance of core products for most companies will meet or exceed its expectations. UBS Group has upgraded 3SBio Inc. (01530.HK) to a top pick, replacing Hansoh Pharma (03692.HK), assigning 3SBio a 'Buy' rating with a target price of HKD 41, citing reasonable valuation. Looking ahead to 2026, the firm predicts the sector's median revenue growth will be 10%, with optimism surrounding innovative drug sales.

AASTOCKSFeb 27 15:49

UBS Group's Investment Ratings and Target Prices for Healthcare Stocks (Table)

UBS Group issued a research report providing investment ratings and target prices for healthcare stocks as follows: Stock | Investment Rating | Target Price (HKD) Hengrui Pharma (01276.HK) | Buy | 96.9 → 98.3 Hansoh Pharma (03692.HK) | Buy | 48.2 → 51.5 China Biologic Products (01177.HK) | Buy | 12.2 3SBio (01530.HK) | Buy | 41 CSPC Pharma (01093.HK) | Neutral | 10 → 10.

AASTOCKSFeb 27 15:48